The enhanced delivery of these DNA vaccines mediated by the electroporation of plasmid (EP) can produce PCAA-specific CD8+T cells and increase their levels in tumor microenvironments, thereby improving the survival of mice carrying prostate cancer 19. Here, CD8A is linked to neoplasm.